A late-stage clinical biopharmaceutical company focused on immunotherapy for various cancers, SELLAS Life Sciences Group (NASDAQ:SLS) is at a genuinely unusual inflection point. Its shares have ...
Stocktwits on MSN
SLS stock pops after-hours as loss shrinks, cash swells — all eyes on high stakes AML trial in 'pivotal' 2026
Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 Regal AML trial nears final analysis, with 72 of 80 required survival events ...
1 of 350 SLS AMG GT Final Editions is for sale with just 1,717 miles. Highlights include carbon fiber elements from the SLS AMG Black Series, forged wheels, and enhanced suspension. 6.2-liter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results